Just.: Just - Evotec Biologics Partners with ABL on Development of Broadly Neutralising Antibody Against HIV

HAMBURG, GERMANY / ACCESSWIRE / June 8, 2020 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its Seattle-based subsidiary Just - Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. ("ABL"), a global contract development and manufacturing organisation ("CDMO") to the U.S. Government and biopharmaceutical industry. This project has been 100% funded with Federal funds under a $ 318.5 m contract from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201700010I/ HHSN27200009.